Management of type-2 diabetes with anti-platelet therapies: Special reference to aspirin

Frontiers in Bioscience - Scholar

Volumn 3 S, Issue 1, 2011, Pages 1-15

  Rao, Gundu H R ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Anti platelet therapy; Aspirin; Aspirin resistance; Clopidogrel; Diabetes management

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ADRENALIN; ARACHIDONIC ACID; CALCIUM ION; CANGRELOR; CILOSTAZOL; CLOPIDOGREL; ELINOGREL; ENDOTHELIN; ENDOTHELIN 1; EPTIFIBATIDE; FATTY ACID SYNTHASE; FIBRINOGEN; GUANYLATE CYCLASE; PADGEM PROTEIN; PICOTAMIDE; PRASUGREL; PROSTACYCLIN; PROTEIN KINASE C; RAMATROBAN; RIDOGREL; SELECTIN; SUPEROXIDE; TERUTROBAN; THROMBOXANE A2; TICAGRELOR; TICLOPIDINE; TIROFIBAN; VON WILLEBRAND FACTOR; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE; THIENOPYRIDINE DERIVATIVE;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; ARACHIDONIC ACID METABOLISM; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; BLEEDING TENDENCY; BLEEDING TIME; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CALCIUM HOMEOSTASIS; CALCIUM MOBILIZATION; CARDIOVASCULAR DISEASE; CELL ACTIVATION; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CLINICAL TRIAL (TOPIC); CONTROLLED RELEASE FORMULATION; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC RETINOPATHY; DRUG ELUTING STENT; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; HEART INFARCTION; HUMAN; HYDROLYSIS; HYPERGLYCEMIA; ISCHEMIC HEART DISEASE; LEUKOCYTE; LOW DRUG DOSE; MACROPHAGE; MAXIMUM PLASMA CONCENTRATION; MONOCYTE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PERIPHERAL VASCULAR DISEASE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SECOND MESSENGER; SECONDARY PREVENTION; SINGLE DRUG DOSE; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOSIS; VASCULAR DISEASE; VASOCONSTRICTION; DRUG RESISTANCE; METABOLISM; PHYSIOLOGY; REVIEW;

ARACHIDONIC ACID; ASPIRIN; BLOOD PLATELETS; DIABETES MELLITUS, TYPE 2; DRUG RESISTANCE; HUMANS; PLATELET AGGREGATION INHIBITORS; THIENOPYRIDINES; TICLOPIDINE; VASCULAR DISEASES;

EID: 79955948538     PISSN: 19450516     EISSN: 19450524     Source Type: Journal    
DOI: 10.2741/s127     Document Type: Article

References (147)

1. Eds. GHR Rao, VV Kakkar Coronary Artery Disease in South Asians: Epidemiology, Risk Factors, and Prevention. Jaypee Medical Publishers, New Delhi, India. (2001)
2. Eds. GHR Rao, S Thanikachalam Coronary Artery Disease in South Asians: Risk Promoters, Pathophysiology, and Prevention. Jaypee Medical Publishers, New Delhi, India. (2005)
3. Eds. V Mohan, GHR Rao Type-2 Diabetes in South Asians: Epidemiology, Risk Factors and Prevention. Jaypee Medical Publishers, New Delhi, India. (2007)
4. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes; Estimates for the year 2000 and projections for 2030. Diabetes Care 27, 1047-1053 (2004) (Pubitemid 38579764)
5. Ramachandran A, Snehalatha C, Vijay V. Temporal changes in prev alence of Type-2 diabetes and impaired glucose tolerance in urban southern India. Diabetes Res. Clin Pract. 58, 55-60 (2002) (Pubitemid 34823625)
6. Mohan V, Deepa M, Deepa R, Shanthiran C, Farooq S, Ganesan A, Dat ta M. Secular trends in the prevalence of diabetes and impaired glucose tolerance in the urban south India-the Chennai Urban Rural Epidemiology Study (CURES-17) Diabetologia 49, 1175-78 (2006)
7. Ramachandran A, Snehalatha C, Kapur A, Vijay V, Mohan V, Das AK, Rao PV, Yajnik CS, Prasanna KM, Nair JD. For the Diabetes Epidemiology Study Group in India (DESI). High prevalence of diabetes and impaired glucose tolera nce in India. National Urban Diabetes Survey. Diabetologia 44, 1094-101 (2001) (Pubitemid 32835500)
8. Diabetes Control Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group, Modern-Day Clinica l Course of Type-1 Diabetes Mellitus After 30 years Duration: The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications and Pittsburgh Epidemiology of Diabetes Complications Experience. Arch Intern Med. 169 , 1307-16 (2009).
9. Clark CM. How should we respond to the worldwide diabetes epidemic? Diab Care 21, 475-76 (1998)
10. Kaufman FR. Type2 Diabetes in Children and Young Adults: A "New Epidemic". Clin. Diabetes 20, 217-18 (2002)
11. Samaras K, Campbell LV. Increasing Incidence ofType-2 Diabetes in the Third Millennium: Is abdominal fat the central issue? Diab Care 23, 441-42 (2000) (Pubitemid 30185782)
12. Permutt MA, Wasson J, Cox N, Genetic epidemiology of diabetes. J Clin Invest 115, 1431-39 (2005) (Pubitemid 40814647)
13. Rao GHR: Physiology of Blood Platelet Activation. Ind J Physiol Pharmacol 37, 263-275 (1993)
14. Ross R: Atherosclerosis-an inflammatory disease. N Engl J Med. 340, 115-26 (1999)
15. Libby P, Ridker PM, Maseri A: Inflammation and atherosclerosis. Circ 105, 1135-43 (2002) (Pubitemid 34212626)
16. Libby P: Current concepts of the pathogenesis of the acute coronary syndromes. Circ 104, 365-72 (2001) (Pubitemid 32666962)
17. Stern MP: Diabetes and cardiovascular disease. The "common soil" hypothesis. Diabetes 44, 369-74 (1995)
18. UN Das: Metabolic syndrome X, type 2 diabetes mellitus and disorders are common in indians: But why and how? In: Coronary Artery Disease: Risk Promoters, Pathophysiology and Prevention. Eds. V Mohan, GHR Rao JP Medical Publishers, New Delhi, India pp73-84 (2005)
19. Celermajer DS, Sorensen KE, Gooch VM, Miller B, Sullivan ID, Lloyd JK, Deanfield JE, Spiegelhalter DJ. Noninvasive detection of endothelial dysfunction in children and adult s at risk of atherosclerosis. Lancet 340, 1111-15 (1992)
20. Ravikumar R, Deepa R, Shanthirani CS. Comparison of carotid intima-medial thickening, arterial stiffness and brachial artery dilation in d iabetic and non-diabetic subjects. A J Cardio 90,702-202 (2002)
21. Sobol AB, Watala C. The role of platelets in diabetes-related vascular complications. Diab Res Clin Pract. 50, 1-16 (2000) (Pubitemid 30629015)
22. Keaney JF, Loscalzo J: Diabetes, oxidative stress and platelet activation. Cir 99, 89-91(1999)
23. Ruoslahti E: Integrins J Clin Invest 87, 1-4. (1991)
24. Ruoslahti E, Pierchbacher MD: New perspectives in cell adhesion. RGD and Integrins. Science 238, 491-97 (1987) (Pubitemid 17147032)
25. Rao GHR: Signal transduction second messengers and platelet function. J Lab Clin Med 121, 18-20 (1993)
26. Rao GHR: Signal transduction second messengers and platelet pharmacology. Pharamcol 13, 39-44 (1994)
27. Hallam TJ: Sanchez A, Rink TJ: Stimulus response coupling in human platelets. Biochem J 218, 819-827 (1984)
28. Seiss W: Molecular mechanisms of platelet activation. Physiology Rev 69, 59-178 (1989)
29. Rana RS, Hokin LE: Role of phosphoinositides in transmembrane signaling. Physiology Rev 70, 115-164 (1990) (Pubitemid 20037283)
30. Hokin LE: Receptors and phosphoinositides generated second messengers. Ann Rev Biochem 54, 205-235 (1985) (Pubitemid 15073646)
31. Marcus AJ: The role of lipids in platelet function: with particular reference to arachidonic acid pathway. J Lipid Res 19, 793-826 (1978) (Pubitemid 9028234)
32. Aukurst P, Waehre T, Damas JK, Gullestad L, Solum NO. Inflammatory role of platelets in acute coronary syndromes. Heart 86, 605-606 (2001) (Pubitemid 33086869)
33. Roth GJ, Stanford N Majerus PW: Acetylation of prostaglandin synthetase by aspirin. Proc Natl Acad Sci USA 72, 3073-76 (1975)
34. Needleman P, Raz A, Minkes MS, Ferrendelli JA, Sprecher H. Triene prostaglandins: prostacyclin and thromboxane biosynthesis and unique biological properties. Proc Nat. Acad Sci USA 76, 944-948 (1979) (Pubitemid 9130979)
35. Hamberg M. Svensson J, Samuelsson B: Mechanisms of anti-aggregating effect of aspirin on human platelets. Lancet 2, 223-224 (1974)
36. Hamberg M, Svensson J, Smuelssson B; Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci 72, 2994-98 (1975)
37. Rao GHR, Rao AT: Pharmacology of Platelet-Activation-Inhibitory Drugs. Ind J Physiol. Pharmacol 38, 69-84 (1994)
38. Rao, GHR: Signal transduction, second messengers and platelet pharmacology. Pharmacol (Life Sci. Adv) 13, 39-44 (1994)
39. Stampler J, Vaccaro O, Wentworth. Diabetes, other risk factors, and 12-Yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabet Care 16, 434-44 (1993) (Pubitemid 23046633)
40. Kannel WB, McGee DL: Diabetes and cardiovascular risk factors: the Framingham study. Circ 59, 8-13 (1979) (Pubitemid 9082394)
41. Bridges JM, Dalby AM, Millar JHD, Weaver JA. An effect of D-glucose on platelet stickiness. Lancet 1, 75-77 (1965)
42. Kwaan HC, Colwell JA, Cruz S, Suwanwela N, Dobbie JG. Increased platelet aggregation in diabetes mellitus. J Lab Clin Med 80, 236-46 (1972)
43. Gerrard JM, Stuart MJ, Rao GHR, Steffes MW, Mauer SM, Brown DM, White JG. Alteration in balance of prostaglandin and thromboxane synthesis in diabetes. J Lab Clin Med 95, 950-57 (1980)
44. Mandal S, Sarode R, Dash S, Dash RJ. Hyperaggregation of platelets detected by whole blood aggregometry in newly diagnosed non-insulin-dependent diabetes mellitus. Am J Clin Pathol 100, 103-37 (1993)
45. Nomura S, Suzuki M, Katsura K, Xie GL, Miyazaki Y, Miyake T, Hirofumi K, Kagawa H, Fukuhara S. Plateletderived microparticles may influence the development of atherosclerosis in diabetes mellitus. Atherosclerosis 116, 235-40 (1995)
46. Tschoepe D, Roesen P, Esser J, Schwippert B, Nieuwenhuis HK, Kehrel B, Gries FA. Large plate lets circulate in an activated state in diabetes mellitus. Sem Thrombo Hemost 17, 433-38 (1991)
47. Tschoepe D, Roesen P, Schwippert B, Gries FA. Platelets in diabetes: the role in the hemostatic regulation in atherosclerosis. Sem Thrombo Hemost 19,122-28 (1993) (Pubitemid 23186843)
48. Fattah MA, Shaheen MH, Mahfouz MH. Disturbances of haemostasis in diabetes mellitus. Dis Markers 19, 251-58 (2004) (Pubitemid 38859469)
49. Deepa R, Mohan V Tissue plasminogen activator, plasminogen activator inhibitor and coronary artery disease in Indians. In: Coronary Artery Disease: Risk Promoters, Pathophysiology and Prevention (Eds. GHR Rao, SThanikachalam, Jaypee Medical Publishers, New Delhi, India pp133-41 (2005)
50. Winocour PD: Platelet abnormalities in diabetes mellitus. Diabetes 41, 26-31 (1992)
51. Kawamori R, Imano E, Watarai T, Nishizawa H, Matsushima H, Kodama M, Yamasaki Y, Kamada T. Platelet activation in diabetic patients with asymptomatic atherosclerosis. Diabetes Res Clin Pract 24, 89-95 (1994) (Pubitemid 24232601)
52. Nakajima S, Noguchi T, Taka T, Ueda T, Kaizu K, Fukamizu M, Fujita S, Tabuchi M, Yamamoto J. A global platelet test of thrombosis and thrombolysis detects a prothrombotic state in some patients with non-insulin dependent diabetes and in some patients with stroke. Platelets 11, 459-66 (2000) (Pubitemid 32147032)
53. Carr ME, Krishnaswami A, Martin EJ. Platelet contractile force (PCF) and clit elastic modulus (CEM) ar e elevated in diabetic patients with chest pain. Diabet Med 19, 862-66 (2002) (Pubitemid 35177188)
54. Gresele P. Gugliemini G, De Angelis M, Ciferri S, Ciofetta M, Falcinelli E, Lalli C, Ciabattoni G, Davi G, Bolli GB. Acute, short-term hyperglycemia enhances shear stress-induced platelet activation in patients with type 11 diabetes mellitus. J Am Coll Cardiol 19, 1013-20 (2003) (Pubitemid 36315547)
55. Cohn JN, Finkelstein JN: Abnormalities of vascular compliance in hypertension, aging and heart failure. J Hypertens 10, S61-S64 (1992)
56. Vane JK, Anggard EE, Botting RM. Regulatory function of the vascular endothelium. N Engl J Med 323, 27-36 (1990)
57. Marcus AJ: The eicosanoids in biology and medicine. J Lipid Res 25, 1511-16 (1984) (Pubitemid 15169466)
58. Ferro CJ, Webb DJ: Endothelial dysfunction and hypertension. Drugs 53, 30-41 (1997) (Pubitemid 27101589)
59. Zeiher A, Dexler A, Wollschlager H. Just H. Modulation of the coronary vasomotor tone in humans: Progressive endothelial dysf unction with different early stages of atherosclerosis. Circ 83, 391-401 (1990)
60. De Meyer GRY, Herman AG: Vascular endothelial dysfunction Prog Cardiovasc Dis 34, 325-42 (1997) (Pubitemid 27120400)
61. Bank AJ: Physiologic aspects of drug therapy. Vasc Med 2, 44-50 (1997)
62. McViegh GE, Allen PB, Morgan DR, Hanratty CG, Silke B. Nitric oxide modulation of blood ves sels tone identified by arterial waveform analysis. Clin Sci. 100, 387-393 (2001) (Pubitemid 32324336)
63. McVeigh GE, Hamilton PK Morgan DR. Evaluation of mechanical properties: clinical experimental and therapeutic aspects. Clin Sci 102, 51-67 (2002) (Pubitemid 34177801)
64. Cohn JN: New approaches to screening for vascular and cardiac risk. Am J Hypertens 14, 2185-2205 (2001)
65. Naidu MUR, Reddy BM, Yashmaina S, Patnaik AN, Rani PU. Validity and reproducibility of arterial pulse wave velocity measurements using a new device with oscillometric technique: A pilot study. Bio Med Eng On Line 4, 49 (2005)
66. Rema M, Mohan V, Deepa R, Ravikumar R. Association of Carotid Intima-Media thickness and arterial stiffness with diabetic retinopathy. The Chennai Urban Epidemiology Study (CURES-2). Diab Care 27, 1962 -67 (2004) (Pubitemid 38989239)
67. Selvin E, Marinopoulos S, Berkenblit S, Rami G. Brancati FL, Powe NR, Golden SH. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 21, 421-31 (2004)
68. Ouvina SM, La Grecca RD, Zanaro NL, Palmer L, Sassetti B. Endothelial dysfunction, nitric oxide and platelet activation in hypertensive and diabetic type II patients. Thromb Res 102, 107-17 (2001)
69. Tretjakovs P, Kalnins U, Dabina I, Erglish A, Dinne I, Jurka G, Zvaigzne A, Pirags V. Nitric oxide production and arachidonic acid metabolism in plat elet membranes of coronary heart disease patients with and without diabetes. Med Prin Pract 12, 10-16 (2003) (Pubitemid 36164648)
70. Huszka M, Kaplar M, Rejto L, Tornai I, Palatka K, Laszle P, Udvardy M. The association of reduced endothelium derived relaxing factor-NO production with endothelial damage and increased in vivo platelet activation in patients with diabetes mellitus. Thromb.Res 86, 173-80 (1997) (Pubitemid 27235129)
71. Pellegatta F, Folli F, Ronchi P, Caspani L, Galli L, Vicari AM. Deranged platelet calcium homeostasis in poorly controlled IDDM patients. Diab Care 16, 178-83 (1993) (Pubitemid 23013842)
72. Schaeffer G, Wascher TC, Kostner GM, Graier WF. Alterations in platelet Ca2+ signaling in diabetic patients is due to increased formation of superoxide anions and reduced nitric oxide production. Diabetol 42, 167-76 (1999) (Pubitemid 29064238)
73. Fukuda K, Ozaki Y, Satoh K, Kume A, Tawata M, Onaya T, Sakurada L, Seto M, Sasaki Y. Phosphorylation of myosin light chain in resting platelets from NIDDM patients is enhanced: correlation with spontaneous aggregation. Diabet 46, 488-93 (1997) (Pubitemid 27090280)
74. Patrono C. Aspirin as an anti-platelet drug. N Engl J Med 330, 1287-1294 (1994)
75. Hanley SP, Cockbill SR, Be van J, Heptinstall S. Differential inhibition by low-dose aspirin of human venous prostacyclin synthesis and platelet thromboxane synthesis. Lancet 2, 969-971 (1981) (Pubitemid 11154969)
76. Keimowitz RM, Pulvermacher G, Mayo G, Fitzgerald DJ. Transdermal modification of platelet function: A dermal aspirin preparation selectively inhibits platelet cyclooxygenase and preserves prostacyclin biosynthesis. Circ 88, 556-561 (1993) (Pubitemid 23228055)
77. Clarke RJ, Mayo G, Price P, Fitzgerald GA. Suppression of thromboxane A2 but not systemic prostacyclin by controlled release aspirin. N Engl J Med 325, 1137-1141 (1991)
78. Antiplatelet Trialists' Collaboration. The Aspirin Papers. Brit J Med 308, 71- 72, 81-106 (1994)
79. Fuster V. Dyken ML, Vokomas PS. Aspirin as a therapeutic agent in cardiovascular disease. Circ 87, 659-675 (1993) (Pubitemid 23040943)
80. Rao GHR, Reddy KR, White JG. Low-dose aspirin, platelet function and prostaglandin synthesis: influence of epinephrine and alpha-adrenergic receptor blockade. Prost and Med. 6, 485-494 (1981)
81. McLeod LJ, Roberts MS, Seville PR. Selective inhibition of platelet cyclooxygenase with controlled release low dose aspirin. Aust. N Z J Med.1990, 20: 652-656.
82. Rao GHR, Radha E Johnson GJ. et al. Enteric coated aspirin, platelet cyclooxygenase activity and platelet function. Prost. Leukot. Med 13, 3-12 (1984)
83. Sullivan MH, Zosmer A, Gleeson RP. Equivalent inhibition of in vivo platelet function by low dose and high dose aspirin. Prost. Leukot Fatty Acids 39, 319-321 (1990) (Pubitemid 20135560)
84. Kyrle PA, Eichler HG, Jager U, Lechner K. Inhibition of prostacyclin and thromboxane A2 generation by low dose aspirin at the site of plug formation in man in vivo. Circ 75, 1025-1029 (1987) (Pubitemid 17068533)
85. Wilson TW, McCauley FA, Wells HD. Effects of low dose aspirin on responses to Fursomide. J Clin Pharmacol 26, 100-105 (1986) (Pubitemid 16166949)
86. Zuc ker Ml, Trowbridge C, Woodroof J, Chernoff SB, Reynoso L, Dujovne CA. Low- vs high-dose aspirin. Effects on platelet function in hyperlipoproteinemc and normal subjects. Arch. Intern Med 146, 921-925 (1986) (Pubitemid 16116673)
87. Davi G, Averna M, Catalano I. Increased thromboxane biosynthesis in type 11a hypercholesterolemia. Circ 85, 1792-1798 (1992)
88. Diminno G, Silver MJ, Cerbone AM, Murphy S. Trial of repeated low-dose aspirin in diabetic angiopathy. Blood 68, 886-891 (1986) (Pubitemid 17183848)
89. Terres W, Schuster O, Kupper W. Bleifeld W. Effects of low-dose acetylsalicylic acid on thrombocy tes in healthy subjects and in patients with coronary heart disease. Dtsh Med Wochenschr 18, 1231-1236 (1989) (Pubitemid 19196875)
90. De Caterina R, Giannessi D, Bernini W, Gazzetti P, Michelassi C, L'Abbate A, Donato L, Patrignani P, Filabozzi P, Patrono C. Low-dose aspirin in patients recovering from myocardial infarction. Evidence for a selective inhibition of thromboxane-related platelet function. Eur Heart J 6, 409-417 ( 1985) (Pubitemid 15045025)
91. Kupper AJ, Verheugt FW, Peels CH, Galema TW, den Hollander W, Roos JP. Effect of low dose acetylsalicylic acid on the frequency and heamtologic activity of left ventricular thrombus in anterior w all acute myocardial infarction. Am J Cardiol 63, 917-920 (1989) (Pubitemid 19105125)
92. Weksler BB, Kent JL, Rudolph D, Scherer PB, Levy DE. Effects of low dose aspirin on platelet function in patients with rec ent cerebral ischemia. Stroke 16, 5-9 (1985) (Pubitemid 15194746)
93. Uchiyama S, Sone R, Nagayama T, Shibagaki Y, Kobayashi I, Maruyama S, Kusakabe K. Combination therapy with low-dose aspirin and ticlop idine in cerebral ischemia. Stroke 20, 1643-1647 (1989) (Pubitemid 20030871)
94. Jones EW, Cockbill SR, Cowley AJ, Hanley SP, Heptinstall S. Effects of dazoxiben and low-dose aspirin on platelet behavior in man. Brit J Pharmacol 15, 395-445 (1983)
95. Rao GHR, White JG. Epinephrine-induced platelet membrane modulation In: The Platelet Amine Storage. Eds: KM Myers, CD Barnes CRC Press, Roca Baton, p117-149 (1992)
96. Rao GHR, Johnson GJ, White JG. Influence of epinephrine on the aggregation response of aspirin-treated platelets. Prost Med 5, 45-58 (1980) (Pubitemid 10064789)
97. Rao GHR, White JG. Epinephrine potentiation of arachidonate-induced aggregation of cyclooxygenase deficient platelets. Am J Hematol 11, 355-366 (1981) (Pubitemid 12248872)
98. Rao GHR, White JG. Role of arachidonic acid in human platelet activation and irreversible aggregation. Am J Hematol 19, 339-347 (1985) (Pubitemid 15004916)
99. Rao GHR, White JG. Aspirin, PGE1 and Quin-2 AM induced platelet dysfunction. Restoration of function by norepinephrine. Prost Leukot Essen Fatty Acids 39, 141-146 (1990) (Pubitemid 20153191)
100. Rao GHR, Escolar G, White JG. Epinephrine reverses the inhibitory influence of aspirin on platelet vessel wall interaction. Thromb Res 44, 65-74 (1986) (Pubitemid 16006895)
101. Rao GHR, Escolar G, Zavrol J. Influence of adrenergic receptor blockade on aspirin-induced inhibition of platelet function. Platelets 1, 145-150 (1990)
102. Rao GHR, Reddy KR, White JG. Modification of human platelet response to sodium arachidonate by membrane modulation. Prost and Med 6, 75-90 (1981) (Pubitemid 11188594)
103. Rao GHR, Johnson GJ, Reddy KR. Ibuprofen Protects Platelet Cyclooxygenase from Irreversible Inhibition by Aspirin. Arteriosclerosis 3, 383-388 (1983) (Pubitemid 13030926)
104. Connelan JM, Thurlow PJ, Barlow B, Lowe M, McKenzie IF. Investigation of alternative mechanisms of collagen-induced platelet activation using monoclonal antibodies to glycoprotein 11b-111a and fibrinogen. Thr omb Haemost 55, 153-157 (1986) (Pubitemid 16013676)
105. Pollack A. For Some, Aspirin May Not Help Hearts. New York Times July (2004)
106. Weber AA, Przytulski B, Schanz A, Hohlfeld T, Schror K. Towards a definition of aspirin resistance: a typological approach. Platelets 13, 37-40 (2002) (Pubitemid 34169586)
107. Yilmaz MB, Balbay Y, Korkmaz S. Aspirin resistance. Anadolu Kardiyol Derg 4, 59-62 (2004) (Pubitemid 38425563)
108. Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G. Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Si de Effects. Chest 126, 2348-2645 (2004)
109. Howard PA. Aspirin resistance. Ann Pharmacother 36, 1620-1624 (2002)
110. Hurlen M, Seijeflot I, Arnesen. The Effect of Different Regimens on Platelet Aggregation After Myocardial Infarction. Scand Cardiovasc J 32, 233-237 (1998) (Pubitemid 28466527)
111. Wu KK, Hoak JC. A new method for the quantitative detection of platelet aggregation in patients with arterial insufficiency. Lancet 11, 924-926 (1974)
112. Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L, Sapp SK, Topol EJ. Profile and prevalence of aspirin resistance inpatients with cardiovascular disease. Am J Cardiol 88, 230-235 (2001) (Pubitemid 32721947)
113. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 41, 961-967 (2003)
114. Deliargyris E, Boudoulas H. Aspirin Resistance. Hellenic J Cardiol 45, 1-5 (2004) (Pubitemid 38176136)
115. Grotemeyer KH. Effects of acetyl salicyclic acid in stroke patients; evidence of non-responders in a subpopulation of treated platelets. Thromb Res 63, 587-593 (1991)
116. Grotemeyer KH. Two-year follow-up of aspirin responder and aspirin non-responder. A pilot-study including 180 post-stroke patients. Thromb Res 71, 397-403 (1993)
117. Mueller MR, Salat A, Stangl P, Murabito M, Pulaki S, Boehm D, Koppensteiner R, Ergun E, Mittlboeck M, Schreiner W, Losert U, Wolner E. Variable plat elet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost 78, 1003-1007 (1997) (Pubitemid 27417291)
118. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circ 105, 1650-1655 (2002) (Pubitemid 34298607)
119. Smout J, Stansby G. Aspirin resistance. Brit J Surgery 89, 4-5 (2002) (Pubitemid 34031301)
120. Helgason CM, Bolin KM, Hoff JA, Winkler SR, Mangat A, Tortorice KL, Bra ce LD. Development of aspirin resistance in persons with previous ischemic stroke. Stroke 25, 2331-2336 (1994) (Pubitemid 24359298)
121. Zimmerman N, Wenk A, Kim U, Kienzle P, Weber AA, Gams E, Schrör K, Hohlfeld T. Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Circ 108, 542-547 (2003) (Pubitemid 36961167)
122. Sane DC, McKee SA, Malinin AI. Frequency of aspirin resistance in patients with congestive heart failure treated with antecedent aspirin. Am J Cardiol 90, 893-895 (2002)
123. Setter SM, Campbell RK, Cahoon CJ. Biochemical Pathways for Microvascular Complications of Diabetes Mellitus. The Ann Pharmacotherapy 37, 1858-66 (2003) (Pubitemid 37466586)
124. Bridges JM, Dalby AM, Miller JHD. Weaver JA. An effect of D-glucose on platelet stickiness. Lancet 1, 75-77 (1965)
125. D'Angelo A, Micossi P, Mannucci PM, Garimberti P et al. Increased production of platelet thromboxane B2 in non-insulin-dependent diabetes: relationship to vascular complications. Eur J Clin Invest 14, 83-86 (1984) (Pubitemid 14133883)
126. Watala C, Boncler M Gressner P. Blood platelet abnormalities and pharmacological modulation of platelet reactivity in patients with diabetes mellitus. Pharmacol Rep 57, 42-58 (2005)
127. Oskarsson HJ, Hofmeyre TG. Platelet from diabetic patients with diabetic mellitus have impaired ability to mediate vasodilation. J Am Coll Cardiol 27, 1464-70 (1996) (Pubitemid 26151682)
128. Davi G, Belvedere M, Vigneri S, Catalano I, Giammarresi C, Roccaforte S, Consoli A, Mez zetti A. Influence of metabolic control on thromboxane biosynthesis and plasma plasminogen inhibitor type-1 in non-insulin-dependent diabetes mellitus. Thromb Hemost 76, 34-37 (1996) (Pubitemid 26254313)
129. Michelson A, Cattaeno M, Eikelbloom JW, Gurbel P, Kottke-Marchant Km Kunicki TJ, Pulcinelli FM, Cetletti C, Rao AK. Aspirin-resistance. Position paper of the working group on aspirin resistance. J Thromb Hemost 3, 1309-11 (2005) (Pubitemid 41725257)
130. DiMinno G, Silver MJ, Murphy AM: Trial of repeated low-dose aspirin in diabetic angiopathy. Blood 68, 886-89 (1986)
131. Joki R, Colwell JA. Arterial thrombosis and atherosclerosis in diabetes. Diab Metab Rev 5, 1-15 (1997)
132. Colwell JA. Aspirin therapy in diabetes (Technical Review). Diab Care 20, 1767-71 (1997) (Pubitemid 27463054)
133. American Diabetes Association, Aspirin Therapy in Diabetes: Position Statement. Diab Care 21, 45-46 (1998)
134. Morrell J. Initiating anti-platelet therapy in diabetes a PCO review. Br J Diabetes Vasc Dis 3,349-53 (2003) (Pubitemid 37336994)
135. Angiolillo DJ. Anti-platelet Therapy in Diabetes: Efficacy and Limitations of Current Treatment Strategies and Future Directions. Diab Care 32, 531-40 (2009)
136. Jalil AN. Hypercoagulation in diabetes mellitus. Southeast Asian J Trop Med Pub Health 1, 263-66 (1993)
137. Carr ME. Diabetes Mellitus: a hypercoagulable state. J Diab Complications 15, 44-54 (2001) (Pubitemid 32203891)
138. Rolka DB, Fagot-Campagna A Narayan KM. Aspirin use among adults with diabetes. Estimates from the Third National Health and Nutrition Examination Survey. Diabt. Care 24, 197-201 (2001) (Pubitemid 32119111)
139. Miller SR. Littenberg B, MacLean CD. Prevalence of anti-platelet therapy in patients with diabetes. Cardio-vasc. Diabetology 4, 18 (2005)
140. Steering Committee of the Physicians' Health Study Group: Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 321, 129-35 (1989)
141. ETDRS Investigators: Aspirin effects on mortality and morbidity in patients with diabetes mellitus. JAMA 268, 1292-300 (1992)
142. Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauci M, Doi N, Jinnouchi H, Sugiyama S, Saito Y. Low dose aspirin for the prevention of atherosclerotic events in patients with type-2 diabetes: a randomized controlled clinical trial. JAMA 300, 2134-41 (2008)
143. Belch H, MacCuish A, Campbell I. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomized placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 337, 1840 (2008)
144. CAPRIE Steering Committee: A randomized, blinded, trial of Clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 348, 1329-39 (1996)
145. Bhatt DL, Marso SP, Hirsch AT, Ringleb, PA, Hack W, Topol EJ. Amplified benefit of Clopidogrel in patients with dia betes mellitus. Am J Cardiol 90, 625-28 (2002) (Pubitemid 35264538)
146. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of Clopidogrel in addition to aspirin in patients with coronary s yndromes without ST-segment elevation. N Engl. J Med 345, 494-502 (2001) (Pubitemid 32758501)
147. Chen K, Rha S, Li Y, Poddar KL, Jin Z, Minami Y, Wang L, Kim EJ, Park CG, Seo HS, Oh DJ, J eong MH, Ahn YK, Hong TJ, Kim YJ, Hur SH, Seong IW, Chae JK, Cho MC, Bae JH, Choi DH, Jang YS, Chae IH, Kim CJ, Yoon JH, Chung WS, Seung KB, Park SJ. Triple versus dual anti-platelet the rapy in patients with acute ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention. Circ 119, 3207-14 (2009)